Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.

Cell reports·2026
Same author

Multimodal PET/CT-based PD-L1 status prediction in lung cancer via semi-supervised and unsupervised deep learning.

Scientific reports·2026
Same author

Role of [<sup>18</sup>F]FDG PET/CT in the monitoring and management of abdominal aortic aneurysms.

Acta cardiologica·2026
Same author

<sup>18</sup>F-FDG PET/CT discriminates whether rheumatoid arthritis patients are in ultrasound remission or not.

Rheumatology advances in practice·2025
Same author

[When PSMA PET/CT imaging unveils the unexpected : a new tool in the diagnosis of hepatocellular carcinoma ?]

Revue medicale de Liege·2025
Same author

Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Related Experiment Video

Updated: Mar 21, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.4K

PET in Brain Tumors.

Roland Hustinx1, Pacôme Fosse1

  • 1Division of Nuclear Medicine, University Hospital of Liège, University of Liège, B35, 4000 Liège I, Belgium.

PET Clinics
|May 10, 2016
PubMed
Summary

Fluorodeoxyglucose (FDG) positron emission tomography (PET) aids glioma evaluation, but alternative tracers like amino-acid analogs offer improved tumor contrast. This review explores PET tracers for brain tumor diagnosis, recurrence detection, and treatment response assessment.

Keywords:
18F-fluorodeoxyglucoseBrain tumorsFETMethyl-L-methioninePositron emission tomography

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.4K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.9K

Related Experiment Videos

Last Updated: Mar 21, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.4K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.4K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.9K

Area of Science:

  • Neuroscience
  • Oncology
  • Radiology

Background:

  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) is historically used for glioma evaluation, showing correlation between tumor grade, prognosis, and uptake intensity.
  • The precise role of FDG PET in neuro-oncology remains under discussion.
  • Alternative PET tracers, including methionine (C11) and fluorinated amino-acid analogs like FET, offer advantages in tumor contrast and biological specificity.

Purpose of the Study:

  • To review the utility of FDG and alternative PET tracers in neuro-oncology.
  • To discuss the application of these tracers in diagnosing and characterizing primary brain tumors.
  • To evaluate their role in detecting recurrence, guiding radiation therapy, and assessing treatment response.

Main Methods:

  • Review of existing literature on FDG PET and alternative tracers (e.g., C11-methionine, FET) for brain tumors.
  • Discussion of the technical and clinical aspects of different PET tracers.
  • Analysis of PET imaging applications in glioma diagnosis, recurrence, and treatment monitoring.

Main Results:

  • FDG PET shows a relationship between tumor grade, prognosis, and uptake, but its exact role is debated.
  • Amino-acid tracers, particularly FET, provide high tumor-to-cortex contrast and have distinct biological properties.
  • The availability of FET has revitalized interest in PET imaging for neuro-oncology.

Conclusions:

  • PET imaging, utilizing tracers like FDG and amino-acid analogs (e.g., FET), is valuable for primary brain tumor management.
  • Alternative tracers offer specific advantages over FDG, especially regarding tumor contrast and biological characterization.
  • PET/CT plays a crucial role in diagnosis, recurrence detection, radiotherapy guidance, and treatment response evaluation in neuro-oncology.